Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML0036

Sigma-Aldrich

Procarbazine hydrochloride

≥98% (HPLC)

Synonym(s):

N-(1-Methylethyl)-4-[(2-methylhydrazinyl)methyl]benzamide hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C12H19N3O·HCl
CAS Number:
366-70-1
Molecular Weight:
257.76
EC Number:
206-678-6
MDL number:
MFCD00072082
UNSPSC Code:
12352200
PubChem Substance ID:
329825106
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to tan

solubility

DMSO: ≥18 mg/mL

storage temp.

2-8°C

SMILES string

Cl.CNNCc1ccc(cc1)C(=O)NC(C)C

InChI

1S/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H

InChI key

DERJYEZSLHIUKF-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Procarbazine hydrochloride has been used to study its physicochemical property.
Procarbazine, an antineoplastic alkylating agent, may be used to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an anticancer agent. It may be used to study new combination of anticancer drugs.

Biochem/physiol Actions

Procarbazine is an antineoplastic alkylating agent widely used in cancer chemotherapy in combination with other compounds. It has multiple mechanisms of action. Procarbazine inhibits protein, RNA and DNA synthesis in addition to being an alkylating agent.
Procarbazine is metabolized to azoprocarbazine either by cytochrome P450 enzyme and monoamine oxidase in an NADPH (nicotinamide adenine diphosphate) dependent or independent manner. It is considered neurotoxic. Procarbazine is used in combination with therapy for treating Hodgkin′s disease.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H302,H341,H350,H360

Hazard Classifications

Acute Tox. 4 Oral - Carc. 1B - Muta. 2 - Repr. 1A

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

N N Sharkunov et al.
Terapevticheskii arkhiv, 84(11), 71-74 (2012-12-21)
To treat patients with different concurrent cancers, including lympho- and myeloproliferative neoplasms, is a difficult task. The paper presents the experience in successfully treating lymphogranulomatosis occurring in a female patient with chronic myeloid leukemia (CML). A combination of the BEACOPP-14
Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies.
Michaela Rancea et al.
Journal of the National Cancer Institute, 104(14), NP-NP (2012-07-25)
eIF2alpha phosphorylation is pathognomonic for immunogenic cell death
Bezu L, et al.
Cell Death and Differentiation, 1-1 (2018)
Eighth Annual Report on Carcinogens, 181-181 (1999)
Soichiro Shibui et al.
Cancer chemotherapy and pharmacology, 71(2), 511-521 (2012-12-12)
Glioblastoma (GBM) is one of the worst cancers in terms of prognosis. Standard therapy consists of resection with concomitant chemoradiotherapy. Resistance to nimustine hydrochloride (ACNU), an alkylating agent, has been linked to methylguanine DNA methyltransferase (MGMT). Daily administration of procarbazine
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service